Helix Biopharma Corp.
HBPCF
$1.71
-$0.02-1.16%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 196.10K | 387.00K | 345.70K | 455.20K | 312.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 502.80K | 668.80K | 697.30K | 1.09M | 909.20K |
| Operating Income | -502.80K | -668.80K | -697.30K | -1.09M | -909.20K |
| Income Before Tax | -511.60K | -726.40K | -691.50K | -1.09M | -967.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -511.60K | -726.40K | -691.50K | -1.09M | -967.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -511.60K | -726.40K | -691.50K | -1.09M | -967.60K |
| EBIT | -502.80K | -668.80K | -697.30K | -1.09M | -909.20K |
| EBITDA | -502.10K | -667.30K | -696.60K | -1.09M | -907.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 76.38M | 75.87M | 70.90M | 53.04M | 50.07M |
| Average Diluted Shares Outstanding | 76.38M | 75.87M | 70.90M | 53.04M | 50.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |